Research-use labeling in the United States
The project list asked for the U.S. legal status of research-use peptides. This draft only records one FDA statement. It is not that full analysis.
What the opened sources say
Section titled “What the opened sources say”- FDA says it has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide, or mazdutide that were falsely labeled “for research purposes” or “not for human consumption.”
- FDA says those products have been sold directly to consumers for human use with dosing instructions, and that they are of unknown quality and may be harmful.
- A separate FDA guidance on research-use-only labeling, and the text of sections 503A and 503B, were not opened for this draft.
Not stated here
Section titled “Not stated here”Do not read this page as permission to sell or buy a product labeled for research.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Regulatory status: Partial note only. FDA research-use-only guidance was not opened for this draft.
Sources
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (primary, accessed 2026-11-20)
Referenced by
A link from another wiki page is not evidence. Facts should point at the sources above.